Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxyTUTION trial
2024-516813-19-00Phase 2Authorised
- Sponsor
- University Hospital Basel
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in arginine vasopressin deficiency (CDI) comparing Oxytocin nasal spray with Placebo nasal spray (2 arms). Primary endpoints: Trait anxiety level after 28 days of treatment and Correct classifications of facial and body expressions after 28 days of treatment. Planned start Jan 2025; status: authorised.
02
Drugs
oxytocin
03
Conditions
arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on 2024-516813-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516813-19-00.